Conference Intelligence Dossier: ESC 2009 Congress, Barcelona
Medical Meeting Outcomes and Insights
Barcelona, September 2009 – The results of three drug trials announced at the prestigious European Society of Cardiology Congress 2009 are expected to have a major impact on cardiovascular clinical practice.
According to FirstWord’s report, Conference Intelligence Dossier: ESC 2009 Congress, Barcelona, critical announcements included AstraZeneca’s PLATO study showing Brilinta’s efficacy, and Boehringer Ingelheim’s RE-LY investigation proving the benefits of Pradaxa over Warfarin. Delegates also heard that Sanofi-aventis hopes to sustain its market share after the Current OASIS-7 study found that doubling the Plavix dose reduced stent thrombosis and major cardiovascular events.
But that’s not all. The congress, held August 28 to September 2, witnessed 9,848 abstracts, 80 industry satellite symposia and workshops, clinical trial hotlines and presentations attended by more than 30,000 international delegates, as well as the latest updates from the ISAR-TEST-4, AAA and SYNTAX studies.
Key Insights from Expert Sources
FirstWord’s report concisely summarizes the 2009 meeting into manageable nodes of information, news and updates which provide instant access to the biggest developments and most important issues facing the world of cardiology. From the impact of new drug developments on both clinical practice and the market to a concise overview of new studies, including design, key results and conclusions, Conference Intelligence Dossier: ESC 2009 Congress, Barcelona offers access and context to the latest news from one of the world’s largest cardiology conferences.
The report:
Barcelona, September 2009 – The results of three drug trials announced at the prestigious European Society of Cardiology Congress 2009 are expected to have a major impact on cardiovascular clinical practice.
According to FirstWord’s report, Conference Intelligence Dossier: ESC 2009 Congress, Barcelona, critical announcements included AstraZeneca’s PLATO study showing Brilinta’s efficacy, and Boehringer Ingelheim’s RE-LY investigation proving the benefits of Pradaxa over Warfarin. Delegates also heard that Sanofi-aventis hopes to sustain its market share after the Current OASIS-7 study found that doubling the Plavix dose reduced stent thrombosis and major cardiovascular events.
But that’s not all. The congress, held August 28 to September 2, witnessed 9,848 abstracts, 80 industry satellite symposia and workshops, clinical trial hotlines and presentations attended by more than 30,000 international delegates, as well as the latest updates from the ISAR-TEST-4, AAA and SYNTAX studies.
Key Insights from Expert Sources
FirstWord’s report concisely summarizes the 2009 meeting into manageable nodes of information, news and updates which provide instant access to the biggest developments and most important issues facing the world of cardiology. From the impact of new drug developments on both clinical practice and the market to a concise overview of new studies, including design, key results and conclusions, Conference Intelligence Dossier: ESC 2009 Congress, Barcelona offers access and context to the latest news from one of the world’s largest cardiology conferences.
The report:
- Key events at the Congress such as clinical trial result announcements, including biographies of the main players and impact analysis
- Logical groupings of compounds presented by type, such as antiplatlet drugs, anticoagulants, statins, angiostensin II receptor antagonists
- Brief outlines of all relevant compound posters
- Additional information relating to presenters, sponsors, drugs monographs and web links to the presentations
- Covers drug updates relating to Brilinta, Pradaxa, Plavix, Effient, Aspirin, Reopro, Crestor, Aprovel, Diovan, Avandia, Procoralan and Lipitor, amongst others.
- Offers insights into new technologies by reporting on non-drug trials such as SYNTAX, TRIANA, ISAR-TEST-4 and MADIT-CRT
EXECUTIVE SUMMARY
CLINICAL TRIAL UPDATES
Antiplatelet drugs
Adeosine diphosphate (ADP) receptor inhibitors
CURRENT OASIS 7 trial - Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions.
TRITON-TIMI 38 trial
PLATO STUDY: Platelet Inhibition and Patient Outcomes Study
Posters on clopidogrel
Cyclooxygenase inhibitors
AAA study- Aspirin for Asymptomatic Atherosclerosis Study
Posters on aspirin
Glycoprotein IIB/IIIA inhibitors (intravenous use only)
PRAGUE 7 STUDY
Anticoagulants
RE-LY Study- Randomised Evaluation of Long-term Anticoagulant therapy (RE-LY)
Statins
GISSI-HF trial
JUPITER Study: Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin.
Posters on Statins
Angiotensin II receptor antagonist
ACTIVE-1 STUDY
KYOTO Study
OTHER CLINICAL TRIALS
RECORD STUDY: The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD) study.
PROTECT STUDY: Prophylaxis for Thromboembolism in Critical Care Trial.
BEAUTIFUL trial
SYNTAX STUDY
MADIT-CRT: Multicentre Automatic Defibrillator Implantation Trial with Cardiac Resynchronisation Therapy) study.
ISAR-TEST-4 STUDY
TRIANA Study
SEPIA-ACS1 TIMI 42
DYSIS STUDY
TNT Study
GRACE Study
BIOGRAPHIES OF KEY PRESENTERS
APPENDIX
SOURCES
CLINICAL TRIAL UPDATES
Antiplatelet drugs
Adeosine diphosphate (ADP) receptor inhibitors
CURRENT OASIS 7 trial - Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions.
TRITON-TIMI 38 trial
PLATO STUDY: Platelet Inhibition and Patient Outcomes Study
Posters on clopidogrel
Cyclooxygenase inhibitors
AAA study- Aspirin for Asymptomatic Atherosclerosis Study
Posters on aspirin
Glycoprotein IIB/IIIA inhibitors (intravenous use only)
PRAGUE 7 STUDY
Anticoagulants
RE-LY Study- Randomised Evaluation of Long-term Anticoagulant therapy (RE-LY)
Statins
GISSI-HF trial
JUPITER Study: Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin.
Posters on Statins
Angiotensin II receptor antagonist
ACTIVE-1 STUDY
KYOTO Study
OTHER CLINICAL TRIALS
RECORD STUDY: The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD) study.
PROTECT STUDY: Prophylaxis for Thromboembolism in Critical Care Trial.
BEAUTIFUL trial
SYNTAX STUDY
MADIT-CRT: Multicentre Automatic Defibrillator Implantation Trial with Cardiac Resynchronisation Therapy) study.
ISAR-TEST-4 STUDY
TRIANA Study
SEPIA-ACS1 TIMI 42
DYSIS STUDY
TNT Study
GRACE Study
BIOGRAPHIES OF KEY PRESENTERS
APPENDIX
SOURCES
